

N-acetyl cysteine prevents ambient fine particulate matter-potentiated atherosclerosis via inhibition of reactive oxygen species-induced oxidized low density lipoprotein elevation and decreased circulating endothelial progenitor cell

YIXIN XU^{1,2}, HAORAN BU^{2,3}, YUFAN JIANG^{1,2}, XIAOQING ZHUO^{2,4}, KE HU⁵,
ZHIHUA SI⁶, YONG CHEN^{2,3}, QIWEI LIU^{1,2}, XIANWEI GONG⁷, HAIHUI SUN^{1,2},
QINGYI ZHU⁸, LIANQUN CUI^{1,2}, XIAOCHUN MA^{9*} and YUQI CUI^{1,2*}

¹Department of Cardiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University;

²Department of Cardiology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University;

³Department of Emergency, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021; ⁴Department of Cardiology, Shandong Second Provincial General Hospital, Shandong University,

Jinan, Shandong 250118; Departments of ⁵Emergency and ⁶Neurology, Qianfoshan Hospital,

Shandong First Medical University, Jinan, Shandong 250014; ⁷Department of Pharmacy,

Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021;

⁸Department of Cardiovascular Medicine, Second Xiangya Hospital, Central South University, Changsha,

Hunan 410008; ⁹Department of Cardiovascular Surgery, Shandong Provincial Hospital Affiliated to

Shandong First Medical University, Jinan, Shandong 250021, P.R. China

Received March 11, 2022; Accepted May 9, 2022

DOI: 10.3892/mmr.2022.12752

Abstract. Ambient fine particulate matter (PM) serves an important role in the development of cardiovascular disease, including atherosclerosis. Antioxidant N-acetyl cysteine (NAC) has protective effects in the cardiovascular system. However, it is unknown if NAC prevents PM-potentiated atherosclerosis in hyperlipidemia. Low-density lipoprotein (LDL) receptor knockout mice were pretreated with 1 mg/ml NAC in drinking water for 1 week and continued to receive NAC, high-fat diet and intranasal instillation of PM for 1 week or 6 months. Blood

plasma was collected for lipid profile, oxidized (ox-)LDL, blood reactive oxygen species (ROS) and inflammatory cytokine (TNF- α , IL-1 β and IL-6) measurement. Blood cells were harvested for endothelial progenitor cell (EPC) population and intracellular ROS analysis. Murine aorta was isolated for atherosclerotic plaque ratio calculation. NAC treatment maintained circulating EPC level and significantly decreased blood ox-LDL and ROS, inflammatory cytokines, mononuclear and EPC intracellular ROS levels as well as aortic plaque ratio. NAC prevented PM-potentiated atherosclerosis by inhibiting plasma ROS-induced ox-LDL elevation, mononuclear cell and EPC intracellular ROS-induced circulating EPC reduction and inflammatory cytokine production.

Correspondence to: Dr Yuqi Cui, Department of Cardiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, 324 Jing 5 Road, Building 3, Jinan, Shandong 250021, P.R. China

E-mail: 42005137@qq.com

Dr Xiaochun Ma, Department of Cardiovascular Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, 324 Jing 5 Road, Building 3, Jinan, Shandong 250021, P.R. China
E-mail: mxcmxc2008@163.com

*Contributed equally

Key words: particulate matter, air pollution, N-acetyl cysteine, endothelial progenitor cells, reactive oxygen species, oxidized low density lipoprotein, hyperlipidemia, inflammation

Introduction

Ambient fine particulate matter (PM) is associated with cardiovascular disease (CVD), including coronary artery disease (CAD), heart failure and hypertension (1). However, the underlying mechanism is not well studied. Different types of CVD may be caused by duration of PM exposure; acute PM exposure increases myocardial infarction (2), stroke (3) and other acute cardiovascular events (4), while chronic exposure contributes to development of hypertension, diabetes and other cardiometabolic conditions (4). Following six months exposure of PM with diameter $\leq 2.5 \mu\text{m}$, atherosclerosis development in apolipoprotein E knockout mice significantly increases and is accompanied by vasomotor tone alteration and vascular inflammation (5). However, the detailed mechanisms

underlying PM-potentiated atherosclerosis in hyperlipidemia is not well studied.

Endothelial dysfunction or injury is a key factor that contributes to the development of atherosclerosis and CAD (6,7). Bone marrow (BM)-derived endothelial progenitor cells (EPCs) serve a key role in vascular reendothelialization, angiogenesis and promotion of neointima formation following vascular injury (8-11). In addition, EPC number and function are significantly decreased in patients with CAD and hyperlipidemia (12,13). However, the exact mechanism underlying decreased EPC levels in patients with hyperlipidemia remains unknown. Oxidized low-density lipoprotein (ox-LDL) is a key component in hyperlipidemia and serves an important role in development of atherosclerosis, primarily via oxidative stress (14). Our previous study indicated that ox-LDL has a similar effect to chronic hyperlipidemia on BM and blood EPC populations (15). However, the effect of PM exposure on ox-LDL and EPC population in hyperlipidemia is still unknown.

Reactive oxygen species (ROS) are small molecules, such as hydrogen peroxide (H_2O_2), that regulate tissue oxidative stress (16). ROS-induced oxidative stress also regulates BM stem cell (BMSC) and BMSC-derived progenitor cell self-renewal, proliferation, mobilization, homing, migration, differentiation, apoptosis and senescence (17,18). Rate of ROS generation in peripheral blood monocytes is increased in hyperlipidemic patients, along with elevated plasma ox-LDL levels, which increases intracellular ROS formation in cultured endothelial cells (19,20). Our previous data showed that PM exposure also increases EPC intracellular ROS production in wild-type (WT) mice (21). To the best of our knowledge, however, ROS production following short- and long-term PM exposure in mice with hyperlipidemia has not been evaluated.

N-acetyl cysteine (NAC) is an antioxidant widely used to investigate CVD (22). Our previous data indicated that NAC prevents atherosclerosis by maintaining EPC population, decreasing both intracellular and extracellular ROS production in hyperlipidemic mice and preventing LDL oxidation in WT mice (15,23). NAC also protects EPCs from apoptosis and decreases levels of inflammatory cytokines following PM exposure in WT mice (21). To the best of our knowledge, however, the effects of NAC on development of atherosclerosis in hyperlipidemic mice with acute and chronic PM exposure has not been investigated. The present study aimed to determine the protective effect and underlying mechanism of NAC on atherosclerosis in mice with hyperlipidemia following acute and chronic PM exposure.

Materials and methods

Animal model. All animal experiments were performed in accordance with the Guidelines of the Animal Care Committee of Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, China. The experimental protocols for the present study were reviewed and approved by the Animal Care Committee of Shandong First Medical University (approval no. 2021-228). A total of 48 4-6-week-old male homozygous C57BL/6J LDL receptor knockout (LDLR KO) mice were obtained from Shanghai Model Organisms Center, Inc. and randomized into 6 groups ($n=8$ /group) as follows: Normal diet

(ND); high-fat diet (HFD); HFD + NAC; PM + ND; PM + HFD and PM + HFD + NAC. In addition to *ad libitum* access to food and water, all mice were kept at room temperature with 40-60% humidity and a 12/12-h light/dark cycle. Following 1 week acclimation, mice were challenged with HFD (17% anhydrous milk fat; 0.2% cholesterol) to induce hyperlipidemia for 1 week or 6 months, as previously described (23). PM (cat. no. NIST2786; mean particle diameter, $<4 \mu m$) was purchased from MilliporeSigma. PM was dispersed in solution by ultrasonication in endotoxin-free water for 30 min at a concentration of $0.5 \mu g/\mu l$ as previously described (24,25). Hyperlipidemic mice were treated with $10 \mu g$ PM three times/week for 1 week or 6 months via intranasal instillation, as previously described (26). Endotoxin-free water was used as control. There are multiple routes for PM to invade the body following inhalation. The primary route is via the respiratory system; other routes include olfactory epithelium and digestive (swallowing sputum with PM) (27). Intranasal instillation was used to mimic natural PM exposure. To evaluate the protective effect of NAC on hyperlipidemic mice with acute and chronic PM exposure, animals were pre-treated with NAC (1 mg/ml in drinking water) for 1 week and continued NAC treatment for 1 week or 6 months, as previously described (23). Mice fed ND were used as control. Although animal health and behavior were monitored every 7 days, 6 mice in the 6-month PM group died before the end of experiment; this may have been due to advanced atherosclerosis development.

Following 1-week or 6-month PM, HFD and NAC treatment, 3.0 and 1.5% isoflurane was used to induce and maintain anesthesia, respectively. A total of 300-500 μl murine blood was collected via cardiac puncture. Then, carbon dioxide (50-70% of chamber volume/min) was used to euthanize the animals. Death was confirmed by cardiac and respiratory arrest or fixed and dilated pupils. Murine aorta was isolated after confirming the death of mice.

Blood lipid, plasma ROS and inflammatory cytokine measurement and atherosclerotic plaque ratio calculation. At the end of the experiment, murine blood was centrifuged at 300 g and room temperature for 20 min to collect plasma for lipid profile, ox-LDL, plasma ROS and inflammatory cytokine analysis. A total of 40 μl plasma was applied in the lipid profile test cassette (Cholestech LDX; cat. no. 10-989; Thermo Fisher Scientific, Inc.) for measuring total cholesterol (TC), triglyceride (TG), LDL, high-density lipoprotein (HDL), non-HDL cholesterol (28) and the ratio of TC/HDL by using Alere Cholestech LDX System. Murine plasma ox-LDL was measured with Ox-LDL ELISA kit (cat. no. CSB-E07933m; Cusabio Technology LLC) according to the manufacturer's instruction. Murine plasma was collected to detect blood ROS levels by using *In Vitro* ROS/Reactive Nitrogen Species (RNS) Assay (cat. no. STA-347; Cell Biolabs, Inc.) and Pierce™ Quantitative Peroxide Assay kit (lipid-compatible formulation; cat. no. 23285; Thermo Fisher Scientific, Inc.) following the manufacturer's instructions. Following incubation of plasma with reagent at room temperature for 30 min, samples were transferred to a 48-well plate for analysis using a microplate reader (Multiskan™ FC Microplate Photometer) at the wavelength of 595 nm to measure the optical density (OD). Plasma levels of inflammatory cytokines TNF- α (cat. no. 430915), IL-1 β (cat. no. 432615) and IL-6 (cat. no. 431315) were

measured using ELISA kits (BioLegend, Inc.) according to the manufacturer's instructions. Murine aorta was dissected and directly stained with oil red (MilliporeSigma) for plaque formation measurement at room temperature for 5 min. The ratio of plaque area to total inner surface of aorta was calculated as previously described (29).

Mononuclear cell and EPC intracellular ROS detection and EPC measurement. An endothelial cell marker combined with a stem cell marker CD34⁺/CD133⁺ was used to identify EPC as previously described (30). Murine blood cells were harvested after sacrifice to detect EPC and mononuclear cell intracellular ROS formation via flow cytometry by using ROS Detection Reagents-FITC (cat. no. D399; Invitrogen; Thermo Fisher Scientific, Inc.) as previously described (31). After removing red blood cells (RBCs) using 1X RBC lysis buffer (cat. no. 00433357; Thermo Fisher Scientific), a total of 50,000 cells in each sample were incubated with 5 μ g/ml ROS Detection Reagents-FITC for 10 min at 37°C. BD™ LSR II (BD Biosciences) at a wavelength of 525 nm was used to calculate the positively fluorescent cells for intracellular ROS detection. For EPC measurement, cells were incubated with anti-mouse CD34-AF700 (cat. no. 560518; BD Biosciences) and CD133-PE (cat. no. 12-1331-82; eBioscience; Thermo Fisher Scientific, Inc.) as previously described (21), then incubated with 5 μ g/ml ROS Detection Reagents-FITC for 10 min at 37°C. Labeled cells were washed twice with PBS and suspended in warm PBS for analysis by flow cytometry on a BD™ LSR II system (BD Biosciences). All antibodies were diluted 1:100.

Statistical analysis. All data are presented as the mean \pm SD (5-8 repeats) and were analyzed using one- or two-way ANOVA (PRISM Version 5.0.; GraphPad Software, Inc.) followed by post hoc conservative Bonferroni's test to minimize type I error. Normal distribution of data was tested using Shapiro-Wilk W-test; equal variance was tested using F-test. When the null hypothesis of normality and/or equal variance was rejected, non-parametric Mann-Whitney U-test was used. Two-tailed $P < 0.05$ was considered to indicate a statistically significant difference.

Results

NAC prevents PM-potentiated atherosclerosis in hyperlipidemia. To test the effect of NAC on atherosclerosis development in hyperlipidemic mice following PM exposure, LDLR KO mice were pre-treated with NAC for 1 week, and continued with NAC, HFD and PM exposure for 6 months. Atherosclerotic plaque formation was increased up to 1.3 fold in PM + HFD compared with HFD mice (Fig. 1). NAC significantly decreased plaque formation in PM + HFD + NAC (0.43 \pm 0.20%) and HFD + NAC (0.42 \pm 0.22%) compared with PM + HFD (0.80 \pm 0.29%) and HFD (0.62 \pm 0.21%) (Fig. 1). There was no plaque formation in any 1 week treatment (data not shown). These results indicated that NAC prevented PM-potentiated atherosclerosis formation.

NAC decreases blood ox-LDL levels following chronic PM exposure in hyperlipidemic mice. The blood lipid levels,




Figure 1. Mouse aortic atherosclerotic formation. Aorta was dissected and stained with oil red for atherosclerotic plaque analysis in LDLR KO mice after HFD with or without PM exposure for 6 months (magnification, x5). A significant amount of atherosclerotic plaque was identified in hyperlipidemic LDLR KO mice with PM exposure (PM + HFD). NAC extensively decreased atherosclerotic plaque area in PM + HFD + NAC and (HFD + NAC) mice. $n=5-8$. * $P < 0.001$ vs. ND; ** $P < 0.001$ vs. HFD; # $P < 0.001$ vs. PM+ND; ## $P < 0.001$ vs. PM + HFD. ND, normal diet; HFD, high-fat diet; NAC, N-acetyl cysteine; PM, ambient fine particulate matter; LDLR, low-density lipoprotein receptor; KO, knockout.

including TC, TG and LDL, were significantly increased in LDLR KO mice treated with HFD for 1 week or 6 months with or without PM exposure compared with ND mice (Table I). NAC had no effect on blood lipid profile in hyperlipidemic mice with or without PM exposure (Table I). Blood ox-LDL levels raised to 2.0 \pm 0.5 nmol/ml in LDLR KO 6-month PM + ND mice compared with 1-week PM + ND mice (0.44 \pm 0.10 nmol/ml; Fig. 2). Furthermore, blood ox-LDL level significantly increased to 14.00 \pm 2.00 nmol/ml in 6-month PM + HFD mice compared with 6-month HFD mice (10.02 \pm 2.21 nmol/ml; Fig. 2). NAC treatment significantly decreased murine plasma ox-LDL levels in LDLR KO mice following 6 month HFD treatment with (PM + HFD + NAC, 6.03 \pm 0.21 nmol/ml) or without PM (HFD + NAC, 5.80 \pm 3.00 nmol/ml) compared with 6-month PM + HFD (14.01 \pm 2.00 nmol/ml) or HFD groups (10.02 \pm 2.21 nmol/ml; Fig. 2). Blood ox-LDL levels were not elevated in any 1 week group compared with ND (Fig. 2). These data suggested that NAC prevented atherosclerosis in association with reducing PM-induced elevation of ox-LDL level in hyperlipidemia.

NAC maintains EPC levels following acute and chronic PM exposure in mice with hyperlipidemia. PM significantly decreased levels of circulating CD34⁺/CD133⁺ cell in LDLR KO mice fed ND for 1 week (0.044 \pm 0.003%) and 6 months (0.010 \pm 0.003%) and further decreased the cell population in PM + HFD mice (1 week, 0.02 \pm 0.01%; 6 months, 0.006 \pm 0.003%; Fig. 3). NAC treatment effectively reversed the effects of PM and hyperlipidemia on EPC (PM + HFD + NAC) in both 1 week (0.05 \pm 0.01%) and 6 month

Table I. Lipid profile of LDL receptor knockout mice.

A, 1 week						
Lipid	ND	HFD	HFD + NAC	PM + ND	PM + HFD	PM + HFD + NAC
TC, mg/dl	228.60±25.66	1162.80±148.13 ^a	1132.80±123.22 ^a	230.60±27.88	1252.80±233.23 ^b	1255.60±114.34 ^b
HDL, mg/dl	88.00±9.64	82.80±6.87	85.40±7.54	90.00±10.24	85.50±7.07	82.50±6.34
TG, mg/dl	148.40±35.47	673.20±123.82 ^a	632.80±87.32 ^a	150.80±36.62	658.30±130.94 ^b	642.50±90.54 ^b
LDL, mg/dl	140.00±0.74	920.60±119.92 ^a	983.80±108.50 ^a	139.00±1.55	898.40±152.72 ^b	884.20±110.30 ^b
Non-HDL, mg/dl	146.40±24.25	1074.80±136.13 ^a	1054.80±103.22 ^a	148.30±26.72	1088.80±140.24 ^b	1059.20±112.32 ^b
TC/HDL	2.61±0.32	14.00±0.74 ^a	13.20±0.85 ^a	2.56±0.52	14.65±0.24 ^b	15.22±0.62 ^b
B, 6 months						
Lipid	ND	HFD	HFD + NAC	PM + ND	PM + HFD	PM + HFD + NAC
TC, mg/dl	228.70±29.02	1704.0±228.70 ^a	1728.00±234.80 ^a	232.50±28.77	1789.00±242.30 ^b	1732.00±243.80 ^b
HDL, mg/dl	76.00±9.80	74.00±24.40	92.00±21.30	78.00±10.10	78.00±25.20	95.00±32.40
TG, mg/dl	103.70±35.00	597.50±217.30 ^a	545.50±197.20 ^a	105.50±42.00	566.40±220.40 ^b	567.40±188.40 ^b
LDL, mg/dl	132.00±23.10	1583.00±100.50 ^a	1576.00±112.20 ^a	140.00±34.20	1602.00±103.20 ^b	1610.00±122.20 ^b
Non-HDL, mg/dl	119.30±83.30	1700.00±90.50 ^a	1720.00±100.60 ^a	122.50±90.50	1689.00±89.50 ^b	1656.00±112.40 ^b
TC/HDL	2.80±0.40	23.00±5.40 ^a	18.78±7.20 ^a	2.98±0.70	22.90±4.40 ^b	18.23±6.90 ^b

Data are presented as the mean ± standard deviation (n=5-8). ^aP<0.01 vs. ND; ^bP<0.01 vs. PM + ND. HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglyceride; TC, total cholesterol; ND, normal diet; HFD, high-fat diet; NAC, N-acetyl cysteine; PM, ambient fine particulate matter.




Figure 2. NAC significantly decreases plasma ox-LDL levels in hyperlipidemic mice with PM exposure. Murine plasma ox-LDL as noticeably increased in 6 month HFD LDLR KO mice and further elevated in 6 month PM + HFD mice compared with 6 month ND and PM + ND respectively. NAC effectively decreased plasma ox-LDL levels in HFD mice with or without PM exposure. n=5-8. *P<0.01 vs. ND; **P<0.01 vs. HFD; #P<0.01 vs. PM + ND; ##P<0.01 vs. PM + HFD. ND, normal diet; HFD, high-fat diet; NAC, N-acetyl cysteine; PM, ambient fine particulate matter; ox-LDL, oxidized low-density lipoprotein; LDLR, low-density lipoprotein receptor; KO, knockout.

(0.03±0.01%) groups compared with 1-week PM + HFD (0.02±0.01%) and 6-month PM + HFD (0.0056±0.0029%) groups respectively. Of note, EPC levels were not altered in 1-week HFD mice (HFD, 0.050±0.002% vs. ND, 0.050±0.005%) and were significantly decreased in 6-month




Figure 3. NAC maintains circulating EPC population in mice with hyperlipidemia following PM exposure. Circulating cells were isolated from LDLR KO mice fed HFD with or without PM exposure. Following red blood cell lysis, murine circulating CD34⁺/CD133⁺ cell population was analyzed by flow cytometry. Circulating EPC levels were significantly decreased in both 1-week and 6-month LDLR KO PM + HFD mice compared with HFD mice. NAC effectively maintained the EPC population. One week PM + ND exposure noticeably decreased EPC population while 1 week HFD had no effect on EPC compared with ND. n=5-8. *P<0.01 vs. ND; **P<0.01 vs. HFD; #P<0.01 vs. PM + ND; ##P<0.01 vs. PM + HFD. ND, normal diet; HFD, high-fat diet; NAC, N-acetyl cysteine; PM, ambient fine particulate matter; LDLR, low-density lipoprotein receptor; KO, knockout; EPC, endothelial progenitor cell.

HFD mice (HFD, 0.02±0.01% vs. ND, 0.040±0.002%). These data demonstrated that NAC prevented PM-induced decrease of EPC in hyperlipidemia.




Figure 4. NAC blocks plasma ROS and both mononuclear and EPC intracellular ROS production in LDLR KO PM + HFD mice fed HFD. Plasma (A) ROS/RNS and (B) H_2O_2 , (C) EPC and (D) mononuclear cell intracellular ROS production were significantly increased in 1 week and 6 month PM + HFD LDLR KO mice. Addition of NAC effectively decreased both plasma ROS and intracellular ROS production. $n=5-8$. * $P<0.01$ vs. ND; ** $P<0.01$ vs. HFD; * $P<0.01$ vs. PM + ND; *** $P<0.01$ vs. PM + HFD. ND, normal diet; HFD, high-fat diet; NAC, N-acetyl cysteine; PM, ambient fine particulate matter; H_2O_2 , hydrogen peroxide; OD, optical density; LDLR, low-density lipoprotein receptor; KO, knockout; EPC, endothelial progenitor cell; ROS, reactive oxygen species; RNS, reactive nitrogen species.

NAC blocks plasma, mononuclear cell and EPC intracellular ROS production in hyperlipidemic mice with acute and chronic PM exposure. Our previous study indicated that increased blood ROS production is associated with increased ox-LDL levels (23) and circulating EPCs are derived from mononuclear cells (32). To determine the mechanism underlying the protective effect of NAC on elevated plasma ox-LDL and decreased circulating EPC levels in mice with hyperlipidemia following acute and chronic PM exposure, plasma ROS, as well as circulating mononuclear cell and EPC intracellular ROS production, was measured in hyperlipidemic mice following 1-week and 6-month PM exposure with or without NAC. Total plasma ROS/RNS and H_2O_2 levels were significantly increased in 1-week PM + HFD mice ($530 \pm 48 \mu M/ml$; 0.33 ± 0.02 OD) or 6 months ($1,255 \pm 110 \mu M/ml$; 0.60 ± 0.01 OD) compared with 1 week HFD mice ($239 \pm 57 \mu M/ml$; 0.12 ± 0.05 OD) or 6 month ($845 \pm 107 \mu M/ml$; 0.45 ± 0.04 OD). NAC significantly blocked plasma ROS production in 1-week (PM + HFD + NAC, $318 \pm 35 \mu M/ml$; 0.13 ± 0.01 OD) or 6-month (PM + HFD + NAC, $480 \pm 88 \mu M/ml$; 0.24 ± 0.02 OD) PM and HFD treated mice compared with 1 week or 6-month PM + HFD mice (Fig. 4A and B). Similarly, mononuclear cell and EPC intracellular ROS production were significantly elevated up to 1.3-1.6-fold in LDLR KO 1-week or 6-month

PM + HFD mice compared with HFD mice (Fig. 4C and D). The increased EPC and mononuclear cell intracellular ROS production were effectively blocked by NAC in 1 week and 6 month PM + HFD + NAC mice (Fig. 4C and D). Of note, ROS production increased in 1 week and 6 month PM + ND mice and 6 month HFD mice compared with 1 week and 6 month ND mice. There was no ROS elevation in 1-week HFD compared with ND mice (Fig. 4A-D). These results indicated that NAC prevented atherosclerosis formation mainly through inhibition of ROS production in hyperlipidemic mice following PM exposure.

NAC effectively inhibits plasma inflammatory cytokine production in hyperlipidemic mice with acute and chronic PM exposure. Our previous study reported that NAC exerts powerful anti-inflammatory effects in WT mice with PM exposure (21). Therefore, the present study investigated whether PM inhibits production of inflammatory cytokines, including TNF- α , IL-1 β and IL-6, in LDLR KO HFD mice. Inflammatory cytokine levels were significantly increased up to 1.3-2.0-fold in LDLR KO 1-week and 6-month PM + HFD mice compared with mice with either HFD or PM + ND (Fig. 5). NAC effectively prevented production of all three cytokines in PM + HFD mice (Fig. 5).




Figure 5. NAC inhibits plasma inflammatory cytokine production in LDLR KO PM + HFD mice. There was a significant increase in TNF- α , IL-1 β and IL-6 in LDLR KO HFD mice with or without PM compared with PM+ND or ND mice. NAC effectively inhibited inflammatory cytokine production. Inflammatory cytokines were also increased in mice with 1 week and 6 month HFD or PM + ND compared with ND mice. $n=5-8$. * $P<0.01$ vs. ND; ** $P<0.01$ vs. HFD; # $P<0.01$ vs. PM + ND; ## $P<0.01$ vs. PM + HFD. ND, normal diet; HFD, high-fat diet; NAC, N-acetyl cysteine; PM, ambient fine particulate matter; LDLR, low-density lipoprotein receptor; KO, knockout.

Discussion

The present study demonstrated that PM exposure potentiated atherosclerosis formation by promoting ox-LDL levels and inflammatory cytokine production and decreasing circulating EPC levels in hyperlipidemic mice. The mechanisms primarily involved elevated ROS production. NAC effectively reversed both acute and chronic PM exposure-potentiated effects in LDLR KO HFD mice.

Cardiovascular risk factors, such as hyperlipidemia, diabetes and age are associated with incomplete revascularization and decreased re-endothelialization following arterial injury in both humans and animals (33-35). Chronic hyperlipidemia exerts harmful effects on the cardiovascular system, including aggravation of atherosclerosis due to elevation of ox-LDL and TG levels and decreased HDL (36). In addition, short-term hyperlipidemia affects organs primarily via initiating inflammation (37-39). On the other hand, PM exposure is associated with atherosclerosis development in both human and animal studies (1,40). The mechanisms primarily involved in PM-potentiated atherosclerosis include early changes in vascular tone via elevated oxidative stress and inflammation, cholesterol modification and promotion of pro-thrombotic reactions (40). The present data indicated that acute and chronic PM exposure in hyperlipidemic mice further increased plasma ox-LDL and inflammatory cytokine levels and decreased circulating EPCs, which serve an important role in endothelial repair (1). The mechanisms primarily involve increased plasma ROS as well as EPC and mononuclear intracellular ROS

production. In addition, males have a higher risk for CVD than females; females are better protected than males against CVD due to undefined mechanisms (41). Our previous study demonstrated that CD34⁺/CD133⁺ EPC population was selectively decreased in male mice following PM exposure via elevated oxidative stress, while PM exposure had no effects on estrogen-independent EPC changes in female mice (42). PM exposure-induced decrease in EPC population in male mice may be due to decreased expression of pulmonary superoxide dismutase 1 (43). Therefore, the regulation of anti-atherosclerotic mechanisms in females requires further investigation. To the best of our knowledge, there is no way to determine the exact amount of PM in respiratory tissue following exposure; however, our previous study indicated that there is increased inflammation in murine pulmonary tissue following PM exposure compared with control (21).

NAC is an antioxidant with therapeutic value for decreasing endothelial dysfunction, inflammation, fibrosis, invasion, cartilage erosion, acetaminophen detoxification and prolong transplant life (44). In cardiovascular studies, NAC protects diabetic heart at risk of myocardial infarction and prevents ischemia- and non-ischemia-associated cardiac damage and ischemia-reperfusion-induced injury primarily via inhibition of oxidative stress in humans (22,45). NAC is also reported to prevent hypertrophy and fibrosis in β -MyHC-Q403 transgenic rabbits and cTnT-Q92 transgenic mice with hypertrophic cardiomyopathy via multiple thiol-responsive mechanisms (46) and inhibit platelet aggregation and reperfusion injury in both human and animals (47).

In accordance with our and other previous studies (23,48-50), the present study demonstrated that NAC had no effect on lipid profile in hyperlipidemia, whereas Korou *et al* (51) found NAC decreases serum LDL levels in hyperlipidemic mice. This difference may be due to different administration methods. Additionally, NAC decreases ox-LDL levels via inhibition of oxidative stress; to the best of our knowledge, however, the detailed mechanism has not previously been investigated (52-54). NAC prevents atherosclerosis formation via suppression of inflammation by inhibiting NF- κ B-induced TNF- α production and blood homocysteine levels (55,56). NAC maintains EPC population, decrease conversion of LDL to ox-LDL *in vivo*, prevent atherosclerosis in humans and mice with hyperlipidemia and promote hind limb ischemia recovery in mice (15,23,30,57).

NAC exhibits protective effects against PM-associated damage in different organs (1). NAC could abolish PM-induced suppression of lymphocyte function in rats and mice (58), inhibits pulmonary inflammation in mice following 5 h and 1 month PM exposure (21,59) and prevents PM-induced ROS production in human endothelial cells (60). To the best of our knowledge, however, the effect of NAC on air pollution-potentiated atherosclerosis has not been reported. Certain studies have reported that NAC prevents senescence of porcine coronary artery endothelial cells *in vitro* (61), attenuates carbon monoxide-induced ischemic heart failure (62), prevents cardiomyocyte apoptosis (63) and inhibits vascular smooth muscle proliferation (64) and heart arrhythmia (65) in rats following PM exposure. The mechanisms include inhibition of oxidative stress, deactivation of c-Jun N-terminal kinase, p38 MAP kinase and inhibition of inflammation via prevention of NF- κ B transcription factor activity (44). NAC prevents apoptosis and promotes cell survival via extracellular signal-regulated kinase activation (44). Our previous studies indicated that NAC inhibits EPC apoptosis, promotes BMSC proliferation and inhibits inflammatory cytokine production via blocking ROS generation in mice following PM exposure for 1 month (21,66). The present data showed that NAC effectively attenuated PM-potentiated atherosclerosis formation via inhibition of plasma ROS-induced ox-LDL elevation and mononuclear cell and EPC intracellular ROS-induced decreases in circulating EPC levels. Of note, blood inflammatory cytokine levels in mice with hyperlipidemia following 1 week or 6 month PM exposure were also significantly decreased by NAC treatment.

Further studies are needed to determine the mechanism of NAC against PM-potentiated atherosclerosis including that underlying NAC-induced decrease in ox-LDL levels, inability of NAC to completely prevent atherosclerosis development and the cell signaling pathways involved in NAC suppression of inflammatory cytokine production.

In conclusion, the present study demonstrated that NAC effectively prevented PM-potentiated atherosclerosis via inhibition of plasma ROS-induced ox-LDL elevation and mononuclear cell and EPC intracellular ROS-induced decrease in circulating EPC levels, as well as suppression of inflammatory cytokine production.

Acknowledgements

Not applicable.

Funding

The present study was supported by The National Nature Science Foundation of China (grant nos. 81600222 and 81800255), Young Experts of Taishan Scholar Program of Shandong Province (grant no. tsqn201812142), Academic Promotion Programme of Shandong First Medical University (grant nos. 2019RC017), The Natural Science Foundation of Shandong Province (grant nos. ZR2016HM22, ZR2018BH002, ZR2020MH044 and ZR2021MH112) and Clinical Medical Science and Technology Innovation Development Plan Project of Jinan in China (grant no. 201704106).

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

YQC, XCM and LQC designed the experiments. YXX, HRB, YFJ, QWL, XWG and XQZ performed the experiments. KH, ZHS, QYZ, YC and HHS collected and analyzed the data. YQC and YXX wrote the manuscript. All authors have read and approved the final manuscript. YQC, XCM and YXX confirm the authenticity of all the raw data.

Ethics approval and consent to participate

All animal procedures were performed in accordance with the Guidelines of the Animal Care Committee of the Shandong Provincial Hospital affiliated to Shandong First Medical University (Jinan, China). The Animal Care Committee of Shandong Provincial Hospital affiliated to Shandong First Medical University (Jinan, China) approved the experimental protocols (approval no. 2021-228).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Cui Y, Sun Q and Liu Z: Ambient particulate matter exposure and cardiovascular diseases: A focus on progenitor and stem cells. *J Cell Mol Med* 20: 782-793, 2016.
2. Liu Y, Pan J, Fan C, Xu R, Wang Y, Xu C, Xie S, Zhang H, Cui X, Peng Z, *et al*: Short-term exposure to ambient air pollution and mortality from myocardial infarction. *J Am Coll Cardiol* 77: 271-281, 2021.
3. Shah AS, Lee KK, McAllister DA, Hunter A, Nair H, Whiteley W, Langrish JP, Newby DE and Mills NL: Short term exposure to air pollution and stroke: Systematic review and meta-analysis. *BMJ* 350: h1295, 2015.
4. Rajagopalan S, Al-Kindi SG and Brook RD: Air pollution and cardiovascular disease: JACC state-of-the-art review. *J Am Coll Cardiol* 72: 2054-2070, 2018.
5. Sun Q, Wang A, Jin X, Natanzon A, Duquaine D, Brook RD, Aguinaldo JG, Fayad ZA, Fuster V, Lippmann M, *et al*: Long-term air pollution exposure and acceleration of atherosclerosis and vascular inflammation in an animal model. *JAMA* 294: 3003-3010, 2005.

6. Davignon J and Ganz P: Role of endothelial dysfunction in atherosclerosis. *Circulation* 109 (23 Suppl 1): III27-III32, 2004.
7. Heitzer T, Schlinzig T, Krohn K, Meinertz T and Munzel T: Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. *Circulation* 104: 2673-2678, 2001.
8. Rauscher FM, Goldschmidt-Clermont PJ, Davis BH, Wang T, Gregg D, Ramaswami P, Pippen AM, Annex BH, Dong C and Taylor DA: Aging, progenitor cell exhaustion, and atherosclerosis. *Circulation* 108: 457-463, 2003.
9. Strehlow K, Werner N, Berweiler J, Link A, Dirnagl U, Priller J, Laufs K, Ghaeni L, Milosevic M, Böhm M and Nickenig G: Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. *Circulation* 107: 3059-3065, 2003.
10. Urbich C and Dimmeler S: Endothelial progenitor cells: Characterization and role in vascular biology. *Circ Res* 95: 343-353, 2004.
11. Werner N, Junk S, Laufs U, Link A, Walenta K, Böhm M and Nickenig G: Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. *Circ Res* 93: e17-e24, 2003.
12. Chen JZ, Zhang FR, Tao QM, Wang XX, Zhu JH and Zhu JH: Number and activity of endothelial progenitor cells from peripheral blood in patients with hypercholesterolaemia. *Clin Sci (Lond)* 107: 273-280, 2004.
13. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM and Dimmeler S: Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. *Circ Res* 89: E1-E7, 2001.
14. Kattoor AJ, Pothineni NVK, Palagiri D and Mehta JL: Oxidative stress in atherosclerosis. *Curr Atheroscler Rep* 19: 42, 2017.
15. Cui Y, Narasimhulu CA, Liu L, Li X, Xiao Y, Zhang J, Xie X, Hao H, Liu JZ, He G, *et al.*: Oxidized low-density lipoprotein alters endothelial progenitor cell populations. *Front Biosci (Landmark Ed)* 20: 975-988, 2015.
16. Auten RL and Davis JM: Oxygen toxicity and reactive oxygen species: The devil is in the details. *Pediatr Res* 66: 121-127, 2009.
17. Ogasawara MA and Zhang H: Redox regulation and its emerging roles in stem cells and stem-like cancer cells. *Antioxid Redox Signal* 11: 1107-1122, 2009.
18. Pervaiz S, Taneja R and Ghaffari S: Oxidative stress regulation of stem and progenitor cells. *Antioxid Redox Signal* 11: 2777-2789, 2009.
19. Cominacini L, Garbin U, Pasini AF, Davoli A, Campagnola M, Pastorino AM, Gaviaraghi G and Lo Cascio V: Oxidized low-density lipoprotein increases the production of intracellular reactive oxygen species in endothelial cells: Inhibitory effect of lacidipine. *J Hypertens* 16: 1913-1919, 1998.
20. Vasconcelos EM, Degasperi GR, de Oliveira HC, Vercesi AE, de Faria EC and Castilho LN: Reactive oxygen species generation in peripheral blood monocytes and oxidized LDL are increased in hyperlipidemic patients. *Clin Biochem* 42: 1222-1227, 2009.
21. Cui Y, Xie X, Jia F, He J, Li Z, Fu M, Hao H, Liu Y, Liu JZ, Cowan PJ, *et al.*: Ambient fine particulate matter induces apoptosis of endothelial progenitor cells through reactive oxygen species formation. *Cell Physiol Biochem* 35: 353-363, 2015.
22. Dłudla PV, Dias SC, Obonye N, Johnson R, Louw J and Nkambule BB: A systematic review on the protective effect of N-Acetyl cysteine against diabetes-associated cardiovascular complications. *Am J Cardiovasc Drugs* 18: 283-298, 2018.
23. Cui Y, Narasimhulu CA, Liu L, Zhang Q, Liu PZ, Li X, Xiao Y, Zhang J, Hao H, Xie X, *et al.*: N-acetylcysteine inhibits in vivo oxidation of native low-density lipoprotein. *Sci Rep* 5: 16339, 2015.
24. Mutlu GM, Green D, Bellmeyer A, Baker CM, Burgess Z, Rajamannan N, Christman JW, Foiles N, Kamp DW, Ghio AJ, *et al.*: Ambient particulate matter accelerates coagulation via an IL-6-dependent pathway. *J Clin Invest* 117: 2952-2961, 2007.
25. Gavett SH, Haykal-Coates N, Highfill JW, Ledbetter AD, Chen LC, Cohen MD, Harkema JR, Wagner JG and Costa DL: World Trade Center fine particulate matter causes respiratory tract hyperresponsiveness in mice. *Environ Health Perspect* 111: 981-991, 2003.
26. Shadie AM, Herbert C and Kumar RK: Ambient particulate matter induces an exacerbation of airway inflammation in experimental asthma: Role of interleukin-33. *Clin Exp Immunol* 177: 491-499, 2014.
27. Holt GR: Effects of air pollution on the upper aerodigestive tract. *Otolaryngol Head Neck Surg* 114: 201-204, 1996.
28. Aggarwal DJ, Kathariya MG and Verma DPK: LDL-C, NON-HDL-C and APO-B for cardiovascular risk assessment: Looking for the ideal marker. *Indian Heart J* 73: 544-548, 2021.
29. Zhuo X, Bu H, Hu K, Si Z, Chen L, Chen Y, Yang L, Jiang Y, Xu Y, Zhao P, *et al.*: Differences in the reaction of hyperlipidemia on different endothelial progenitor cells based on sex. *Biomed Rep* 15: 64, 2021.
30. Cui Y, Liu L, Xiao Y, Li X, Zhang J, Xie X, Tian J, Sen CK, He X, Hao H and Liu Z: N-acetylcysteine differentially regulates the populations of bone marrow and circulating endothelial progenitor cells in mice with limb ischemia. *Eur J Pharmacol* 881: 173233, 2020.
31. Rosenkranz AR, Schmaldienst S, Stuhlmeier KM, Chen W, Knapp W and Zlabinger GJ: A microplate assay for the detection of oxidative products using 2',7'-dichlorofluorescein-diacetate. *J Immunol Methods* 156: 39-45, 1992.
32. Eggermann J, Kliche S, Jarmy G, Hoffmann K, Mayr-Beyrle U, Debatin KM, Waltenberger J and Beltinger C: Endothelial progenitor cell culture and differentiation in vitro: A methodological comparison using human umbilical cord blood. *Cardiovasc Res* 58: 478-486, 2003.
33. Ii M, Takenaka H, Asai J, Ibusuki K, Mizukami Y, Maruyama K, Yoon YS, Wecker A, Luedemann C, Eaton E, *et al.*: Endothelial progenitor thrombospondin-1 mediates diabetes-induced delay in reendothelialization following arterial injury. *Circ Res* 98: 697-704, 2006.
34. Kinnaird T, Stabile E, Zbinden S, Burnett MS and Epstein SE: Cardiovascular risk factors impair native collateral development and may impair efficacy of therapeutic interventions. *Cardiovasc Res* 78: 257-264, 2008.
35. Sodha NR, Clements RT, Boodhwani M, Xu SH, Laham RJ, Bianchi C and Sellke FW: Endostatin and angiostatin are increased in diabetic patients with coronary artery disease and associated with impaired coronary collateral formation. *Am J Physiol Heart Circ Physiol* 296: H428-H434, 2009.
36. Panahi Y, Ahmadi Y, Teymouri M, Johnston TP and Sahebkar A: Curcumin as a potential candidate for treating hyperlipidemia: A review of cellular and metabolic mechanisms. *J Cell Physiol* 233: 141-152, 2016.
37. Krauzova E, Kracmerova J, Rossmeislova L, Mališová L, Tencerová M, Koc M, Štich V and Šiklová M: Acute hyperlipidemia initiates proinflammatory and proatherogenic changes in circulation and adipose tissue in obese women. *Atherosclerosis* 250: 151-157, 2016.
38. He L, Hao L, Fu X, Huang M and Li R: Severe hypertriglyceridemia and hypercholesterolemia accelerating renal injury: A novel model of type 1 diabetic hamsters induced by short-term high-fat/high-cholesterol diet and low-dose streptozotocin. *BMC Nephrol* 16: 51, 2015.
39. Krysiak R, Zmuda W, Marek B and Okopien B: Comparison of the effects of short-term hypolipidaemic treatment on plasma adipokine levels in men and women with isolated hypercholesterolaemia. *Endokrynol Pol* 66: 114-120, 2015.
40. Bevan GH, Al-Kindi SG, Brook R and Rajagopalan S: Ambient air pollution and atherosclerosis: Recent updates. *Curr Atheroscler Rep* 23: 63, 2021.
41. Kander MC, Cui Y and Liu Z: Gender difference in oxidative stress: A new look at the mechanisms for cardiovascular diseases. *J Cell Mol Med* 21: 1024-1032, 2017.
42. Liu X, Xiao Y, Zhu Q, Cui Y, Hao H, Wang M, Cowan PJ, Korthuis RJ, Li G, Sun Q and Liu Z: Circulating endothelial progenitor cells are preserved in female mice exposed to ambient fine particulate matter independent of estrogen. *Int J Mol Sci* 22: 7200, 2021.
43. Liu X, Wang A, Chen Z, Cui Y, Hao H, Domeier TL, Sun Q and Liu Z: Tempol preserves endothelial progenitor cells in male mice with ambient fine particulate matter exposure. *Biomedicines* 10: 327, 2022.
44. Zafarullah M, Li WQ, Sylvester J and Ahmad M: Molecular mechanisms of N-acetylcysteine actions. *Cell Mol Life Sci* 60: 6-20, 2003.
45. Bartekova M, Barancik M, Ferenczyova K and Dhalla NS: Beneficial effects of N-acetylcysteine and N-mercaptopropionylglycine on ischemia reperfusion injury in the heart. *Curr Med Chem* 25: 355-366, 2018.
46. Marian AJ: Experimental therapies in hypertrophic cardiomyopathy. *J Cardiovasc Transl Res* 2: 483-492, 2009.
47. Nikbakht M, Ahmadi F, Vaseghi G, Talasaz AH, Eshraghi A, Naderi J and Daneshmehr MA: The role of N-acetylcysteine in platelet aggregation and reperfusion injury in recent years. *Curr Clin Pharmacol* 12: 83-91, 2017.

48. Lin CP, Huang PH, Lai CF, Chen JW, Lin SJ and Chen JS: Simvastatin attenuates oxidative stress, NF- κ B activation, and artery calcification in LDLR-/-mice fed with high fat diet via down-regulation of tumor necrosis factor- α and TNF receptor 1. *PLoS One* 10: e0143686, 2015.
49. Subrahmanian S, Varshney R, Subramani K, Murphy B, Woolington S and Ahamed J: N-Acetylcysteine inhibits aortic stenosis progression in a murine model by blocking Shear-induced activation of platelet latent transforming growth factor beta 1. *Antioxid Redox Signal*: Dec 7, 2021 (Epub ahead of print).
50. Spartalis M, Siasos G, Mastrogeorgiou M, Spartalis E, Kaminiotis VV, Mylonas KS, Kapelouzou A, Kontogiannis C, Doulamis IP, Toutouzou K, *et al*: The effect of per os colchicine administration in combination with fenofibrate and N-acetylcysteine on triglyceride levels and the development of atherosclerotic lesions in cholesterol-fed rabbits. *Eur Rev Med Pharmacol Sci* 25: 7765-7776, 2021.
51. Korou LM, Agrogiannis G, Pantopoulou A, Vlachos IS, Iliopoulos D, Karatzas T and Perrea DN: Comparative antilipidemic effect of N-acetylcysteine and sesame oil administration in diet-induced hypercholesterolemic mice. *Lipids Health Dis* 9: 23, 2010.
52. Meng XP, Yin CS, Cui JH, Li ZX, Wang L, Wang YW and Li YL: Inhibitory effect of N-acetylcysteine upon atherosclerotic processes in rabbit carotid. *Zhonghua Yi Xue Za Zhi* 89: 1850-1853, 2009 (In Chinese).
53. Sung HJ, Kim J, Kim Y, Jang SW and Ko J: N-acetyl cysteine suppresses the foam cell formation that is induced by oxidized low density lipoprotein via regulation of gene expression. *Mol Biol Rep* 39: 3001-3007, 2012.
54. Thiele H, Hildebrand L, Schirdewahn C, Eitel I, Adams V, Fuernau G, Erbs S, Linke A, Diederich KW, Nowak M, *et al*: Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate Percutaneous Coronary Intervention Acute Myocardial Infarction N-ACC) Trial. *J Am Coll Cardiol* 55: 2201-2209, 2010.
55. Poitevin S, Garnotel R, Antonicelli F, Gillery P and Nguyen P: Type I collagen induces tissue factor expression and matrix metalloproteinase 9 production in human primary monocytes through a redox-sensitive pathway. *J Thromb Haemost* 6: 1586-1594, 2008.
56. Wiklund O, Fager G, Andersson A, Lundstam U, Masson P and Hultberg B: N-acetylcysteine treatment lowers plasma homocysteine but not serum lipoprotein(a) levels. *Atherosclerosis* 119: 99-106, 1996.
57. Zhu Q, Hao H, Xu H, Fichman Y, Cui Y, Yang C, Wang M, Mittler R, Hill MA, Cowan PJ, *et al*: Combination of antioxidant enzyme overexpression and N-acetylcysteine treatment enhances the survival of bone marrow mesenchymal stromal cells in ischemic limb in mice with type 2 diabetes. *Am Heart Assoc* 10: e023491, 2021.
58. Omara FO, Fournier M, Vincent R and Blakley BR: Suppression of rat and mouse lymphocyte function by urban air particulates (Ottawa dust) is reversed by N-acetylcysteine. *J Toxicol Environ Health A* 59: 67-85, 2000.
59. Rhoden CR, Lawrence J, Godleski JJ and Gonzalez-Flecha B: N-acetylcysteine prevents lung inflammation after short-term inhalation exposure to concentrated ambient particles. *Toxicol Sci* 79: 296-303, 2004.
60. Wang T, Wang L, Moreno-Vinasco L, Lang GD, Siegler JH, Mathew B, Usatyuk PV, Samet JM, Geyh AS, Breysse PN, *et al*: Particulate matter air pollution disrupts endothelial cell barrier via calpain-mediated tight junction protein degradation. *Part Fibre Toxicol* 9: 35, 2012.
61. Sharma K, Lee HH, Gong DS, Park SH, Yi E, Schini-Kerth V and Oak MH: Fine air pollution particles induce endothelial senescence via redox-sensitive activation of local angiotensin system. *Environ Pollut* 252(Pt A): 317-329, 2019.
62. Reboul C, Boissiere J, Andre L, Meyer G, Bideaux P, Fouret G, Feillet-Coudray C, Obert P, Lacampagne A, Thireau J, *et al*: Carbon monoxide pollution aggravates ischemic heart failure through oxidative stress pathway. *Sci Rep* 7: 39715, 2017.
63. Kim JB, Kim C, Choi E, Park S, Park H, Pak HN, Lee MH, Shin DC, Hwang KC and Joung B: Particulate air pollution induces arrhythmia via oxidative stress and calcium calmodulin kinase II activation. *Toxicol Appl Pharmacol* 259: 66-73, 2012.
64. Tzeng HP, Yang RS, Ueng TH and Liu SH: Upregulation of cyclooxygenase-2 by motorcycle exhaust particulate-induced reactive oxygen species enhances rat vascular smooth muscle cell proliferation. *Chem Res Toxicol* 20: 1170-1176, 2007.
65. Rhoden CR, Wellenius GA, Ghelfi E, Lawrence J and Gonzalez-Flecha B: PM-induced cardiac oxidative stress and dysfunction are mediated by autonomic stimulation. *Biochim Biophys Acta* 1725: 305-313, 2005.
66. Cui Y, Jia F, He J, Xie X, Li Z, Fu M, Hao H, Liu Y, Liu DZ, Cowan PJ, *et al*: Ambient fine particulate matter suppresses in vivo proliferation of bone marrow stem cells through reactive oxygen species formation. *PLoS One* 10: e0127309, 2015.



This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.